Anavex Life Sciences Corp. filed a Form 8-K on November 2, 2026, disclosing the simultaneous resignation of three board members on October 28, 2026, each citing misalignment with the company's strategic direction, and reporting the reconstitution of all three standing board committees.

Key Highlights

  • Three resignations on the same day: Dr. Jiong Ma, Mr. Gautam Patel, and Dr. Adrian Senderowicz each resigned from the Anavex Life Sciences Corp. Board of Directors effective October 28, 2026.
  • Chair departure: Dr. Jiong Ma served as Chair of the Board and a member of the Audit Committee prior to her resignation.
  • Stated reason - Ma: According to the filing, Dr. Ma's resignation letter states that "her views about the Company's strategic direction are not fully aligned with those of the Board and management."
  • Stated reason - Patel and Senderowicz: Both Mr. Patel and Dr. Senderowicz stated in their respective resignation letters that their "personal views regarding the Company's strategy to execute its business plan do not sufficiently align with those of the Board and management."
  • Committee reconstitution: On November 1, 2026, the Board approved the reconstitution of its Audit, Compensation, and Nominating and Corporate Governance Committees with the remaining directors Dr. Claus van der Velden, Dr. Peter Donhauser, and Dr. Axel Paeger.
  • Response process: The company disclosed it provided each resigning director the opportunity to submit a letter agreeing or disagreeing with the company's characterizations, and will file any such letter as an exhibit to an amendment within two business days of receipt.

Three Anavex Directors Depart Over Strategy Disagreements, Committees Restructured

Anavex Life Sciences Corp. (NASDAQ:AVXL) reported in a current report filed November 2, 2026 that Dr. Jiong Ma, Mr. Gautam Patel, and Dr. Adrian Senderowicz resigned from its Board of Directors on October 28, 2026. The filing covers these departures under Item 5.02, which addresses the departure of directors or certain officers. All three resignations took effect on the same date.

Prior to resigning, Dr. Ma held the position of Chair of the Board and was a member of the Audit Committee. Mr. Patel served as a member of the Audit Committee. Dr. Senderowicz, according to the filing, "was not serving on any Board committees" at the time of his resignation. Each of the three individuals submitted a resignation letter, which the company filed as Exhibits 17.1, 17.2, and 17.3, respectively. The filing notes that each letter cited a lack of alignment with the company's strategic direction or its strategy to execute its business plan as the reason for departure.

Following the departures, the Board on November 1, 2026 approved the reconstitution of its three standing committees. The Audit Committee will be chaired by Dr. Claus van der Velden, with Dr. Peter Donhauser and Dr. Axel Paeger as members. The Compensation Committee will be chaired by Dr. Peter Donhauser, with Dr. Claus van der Velden as a member. The Nominating and Corporate Governance Committee will be chaired by Dr. Axel Paeger, with Dr. Peter Donhauser as a member. The filing was signed by Sandra Boenisch, CPA, CGA, Principal Financial Officer and Treasurer.

What Was Disclosed

Anavex Life Sciences Corp. disclosed the October 28, 2026 resignations of three board members, each citing strategic misalignment, and the November 1, 2026 reconstitution of its Audit, Compensation, and Nominating and Corporate Governance Committees among the remaining directors.